Boston Scientific BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. 10-K, Item 1
- Employees
- 59,000
- Headquarters
- Marlborough, MA
- CEO
- Michael F. Mahoney
- Next results
- around Feb 3, 2027
Where each dollar of revenue went, FY2025
Revenue of $20.1B through the costs to a net profit of $2.9B · income statement of the 10-K
BSX among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.
What changed
3 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 17, 2026 against Feb 18, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Valuation of intangible assets acquired in business combinations (“As disclosed in Note B to the consolidated financial statements, during 2025, the Company completed the acquisitions of Bolt Medical, Inc. and SoniVie Ltd. for purchase prices, net of cash acquired, of $782 million and $516 million, respectively.”)
-
Receivables +14.4% vs revenue +19.9% (-5.5 pts)
9 more checks with nothing to note
-
Cash from operations $4.5B vs net income $2.9B (FY ending Dec 31, 2025)
-
Inventory +4.7% vs revenue +19.9% (-15.1 pts)
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
3 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
Our business and operations are subject to risks related to natural disasters, climate change and other extreme weather.
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
We are subject to certain U.S. tariffs that are currently subject to legal challenge before the U.S. Supreme Court. The timing and outcome of this litigation are uncertain, and the Court’s decision could result in the modification, invalidation, or continuation of such tariffs. Any modification of existing tariffs, or the introduction…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $12.7B | $14.2B | $16.7B | $20.1B |
| Net income | $642.0M | $1.6B | $1.9B | $2.9B |
| Operating cash flow | $1.5B | $2.5B | $3.4B | $4.5B |
| Free cash flow | $938.0M | $1.8B | $2.6B | $3.7B |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$20.1B ▲ 19.9% in FY2025$2.9B ▲ 56.4% in FY2025$3.7B ▲ 38.3% in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 2, 2026Michael F. Mahoney (Chairman and Chief Executive Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 98,814 shares
-
10-QNov 2, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KOct 28, 2026Quarterly results 8-K item 2.02
About the company
Boston Scientific, Marlborough, MA · from the 10-K filed Feb 17, 2026
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body.
- Headquarters
- Marlborough, MA
- Country
- United States
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Oct 28, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had approximately 59,000 employees, of which approximately 60 percent were outside the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BSX/export.csv") into a cell.